SCHEMBL6791191

SCHEMBL6791191

O=C1NC(=O)C(C(O)c2ccc(-c3ccc(Cl)cc3)cc2)N1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
BRD4 O60885 1/20 0.34
HSD17B2 P37059 1/20 0.34
ALDH1A1 P00352 3/20 0.33
FFAR1 O14842 1/20 0.33
TSHR P16473 3/20 0.32
ADAMTS5 Q9UNA0 1/20 0.32
KDM4E B2RXH2 2/20 0.32
TDP2 O95551 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
HIF1A Q16665 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
AHR P35869 1/20 0.32
NOTUM Q6P988 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786610 0.88 HSD17B2 (0.40) HSD17B2ALDH1A1FFAR1GAA
SCHEMBL6798684 0.88 HSD17B2 (0.40) HSD17B2ALDH1A1FFAR1GAA
SCHEMBL6798968 0.88 HSD17B2 (0.40) HSD17B2ALDH1A1FFAR1GAA
SCHEMBL6800602 0.86 TDP1 (0.45) HSD17B2ALDH1A1FFAR1TSHRADAMTS5
SCHEMBL6793693 0.82 LMNA (0.42) MMP2MMP9MMP8HSD17B2ALDH1A1
SCHEMBL6703699 0.81 BACE1 (0.32) TSHRTDP1
SCHEMBL10620249 0.80 ALDH1A1 (0.41) HSD17B2ALDH1A1KDM4ELMNAMAPK1
SCHEMBL6702888 0.79 HSD17B2 (0.41) HSD17B2ALDH1A1TSHRADAMTS5TP53
SCHEMBL6791466 0.77 PTPRC (0.41) HSD17B2ALDH1A1KDM4EHPGDMEN1
SCHEMBL6702161 0.77 CES2 (0.41) MMP2MMP8HSD17B2FFAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MMP2 2/4885MMP9 1/4885MMP8 19/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP2 11/4885MMP9 8/4885MMP8 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.